Needham Out Positive On Cara Therapeutics After Positive Phase 3 CR845 Results, Raising Price Target to $28, Assumes Another Phase 3 Trial could Be Initiated Early '19 and Estimates Commercial Launch 2H21

Never miss a trade again with the fastest news alerts in the world!

This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday.

Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters? Join 10,000+ serious traders in the Benzinga Pro community!